Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety of a novel therapeutic scheme in patients with unresectable CholAngiocarcinoma; RadioEmbolization in combination with CisGem and Durvalumab)
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PM-CARE
Most Recent Events
- 06 Sep 2023 New trial record